TAK-285 is primarily investigated for its use in cancer therapy, specifically as a dual inhibitor of HER2 and EGFR tyrosine kinases. These proteins are involved in signaling pathways that promote cell growth and are often overactive in certain cancers, such as breast and gastric cancers. By inhibiting these kinases, TAK-285 helps suppress uncontrolled tumor cell proliferation and survival. It has shown potential in preclinical studies for treating solid tumors, particularly those resistant to existing therapies. Its development aimed to improve selectivity and reduce side effects compared to earlier kinase inhibitors. While clinical development has been limited, TAK-285 remains a reference compound in the design of new targeted oncology drugs.